At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
MGD007 + MGA012biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory Metastatic Colorectal Carcinoma
In Brief
A Phase 2 clinical trial evaluating MGD007 + MGA012 for Colorectal Cancer Metastatic. Completed, enrolled 38 participants across 6 sites.
Detailed Summary
The primary goal of this study is to characterize the safety, tolerability, and maximum tolerated dose (MTD) of MGD007 when combined with MGA012. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of the combination of MGD007 and MGA012 will also be assessed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer Metastatic
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJun 2018
Primary CompletionFeb 2020
TodayJul 2026
First PostedMay 22, 2018
Enrollment StartJun 4, 2018
Primary CompletionFeb 8, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.1 years ago
Interventions
MGD007 + MGA012biological
MGD007 and MGA012 are administered by IV infusion.